Please assess the completion status of the following clinical trial:

Trial Title: Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have received 3 infusions in the HORIZON-Pivotal Fracture (PFT) Study.~Exclusion Criteria:~* Poor kidney, eye, or liver health~* Use of certain therapies for osteoporosis in the HORIZON-PFT study (other than the study medication)~* Abnormal calcium levels in the blood~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 68 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Zoledronic Acid 6 (Type: EXPERIMENTAL): Patients who received Zoledronic acid for 3 years in the core study (CZOL446H2301; NCT00049829) received a single intravenous infusion of 5 mg Zoledronic acid once a year for 3 years (at Months 36, 48 and 60) in this extension study for a total of 6 years of treatment.
- Zoledronic Acid 3 Placebo 3 (Type: PLACEBO_COMPARATOR): Patients who were treated with Zoledronic acid for 3 years in the core study received a single intravenous matching Placebo infusion once a year for 3 years in this extension study.
- Placebo 3 Zoledronic Acid 3 (Type: EXPERIMENTAL): Patients who were treated with placebo for 3 years in the core study received 5 mg Zoledronic acid in a single intravenous infusion once a year for 3 years (at Months 36, 48 and 60) in this extension study.

Based on this trial design, predict the completion outcome and termination type (if applicable).